PT Sarana Meditama Metropolitan Tbk Logo

PT Sarana Meditama Metropolitan Tbk

SAME.JK

(1.8)
Stock Price

244 IDR

0.18% ROA

0.24% ROE

602.13x PER

Market Cap.

5.247.012.599.694 IDR

26.73% DER

0% Yield

0.52% NPM

PT Sarana Meditama Metropolitan Tbk Stock Analysis

PT Sarana Meditama Metropolitan Tbk Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

PT Sarana Meditama Metropolitan Tbk Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a minimal amount of debt (21%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

2 ROE

The stock's ROE falls within an average range (0.81%), demonstrating satisfactory profitability and efficiency in utilizing shareholders' equity.

3 ROA

The stock's ROA (0.64%) shows that it's doing a pretty good job at making money from its assets, making it a solid choice to invest and earn steady profits.

4 PBV

The stock's PBV ratio (1.46x) reflects a fair valuation, making it an attractive option for investors seeking balanced opportunities.

5 Assets Growth

Company's revenue has experienced consistent growth over the last three years, indicating a favorable financial trajectory and making it an attractive investment choice.

6 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock appears undervalued (15.033), presenting an attractive investment chance with its intrinsic value surpassing the current market price.

7 Revenue Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

8 Net Profit Growth

Throughout the last five years, this company's net profit has remained unchanged, indicating a lack of growth and making it a less favorable investment option.

9 Graham Number

The Graham number analysis indicates that this company's stock price is likely overpriced, raising concerns about its investment potential.

10 Dividend Growth

The company's dividend growth has remained flat for the past three years, offering no indication of improved returns and making it a less advantageous investment opportunity.

11 Dividend

No dividends from the company in the past three years raises doubts about its profitability for shareholders.

PT Sarana Meditama Metropolitan Tbk Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

PT Sarana Meditama Metropolitan Tbk Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Sell
2 MACD Sell
3 RSI Hold
4 Stoch RSI Buy

PT Sarana Meditama Metropolitan Tbk Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

PT Sarana Meditama Metropolitan Tbk Revenue
Year Revenue Growth
2012 270.468.256.130
2013 336.510.610.535 19.63%
2014 414.414.878.128 18.8%
2015 515.094.720.932 19.55%
2016 635.020.760.619 18.89%
2017 775.567.241.680 18.12%
2018 952.082.106.918 18.54%
2019 529.319.793.872 -79.87%
2020 507.616.889.306 -4.28%
2021 1.271.584.061.675 60.08%
2022 1.393.542.157.498 8.75%
2023 1.636.197.442.996 14.83%
2023 1.535.639.515.741 -6.55%
2024 1.647.576.447.288 6.79%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

PT Sarana Meditama Metropolitan Tbk Research and Development Expenses
Year Research and Development Expenses Growth
2012 0
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

PT Sarana Meditama Metropolitan Tbk General and Administrative Expenses
Year General and Administrative Expenses Growth
2012 20.798.473.397
2013 26.845.729.977 22.53%
2014 31.863.844.649 15.75%
2015 39.079.960.372 18.47%
2016 44.576.187.961 12.33%
2017 46.988.258.931 5.13%
2018 61.995.080.414 24.21%
2019 45.885.556.717 -35.11%
2020 58.550.731.804 21.63%
2021 97.406.089.452 39.89%
2022 117.135.075.078 16.84%
2023 126.089.502.640 7.1%
2023 122.236.395.787 -3.15%
2024 74.129.172.056 -64.9%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

PT Sarana Meditama Metropolitan Tbk EBITDA
Year EBITDA Growth
2012 61.981.086.165
2013 85.949.534.982 27.89%
2014 107.239.454.644 19.85%
2015 111.788.514.848 4.07%
2016 119.088.603.887 6.13%
2017 189.930.743.658 37.3%
2018 204.749.119.337 7.24%
2019 51.705.616.150 -295.99%
2020 68.994.139.209 25.06%
2021 278.847.427.259 75.26%
2022 159.663.932.642 -74.65%
2023 235.565.994.920 32.22%
2023 274.673.157.930 14.24%
2024 309.784.591.320 11.33%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

PT Sarana Meditama Metropolitan Tbk Gross Profit
Year Gross Profit Growth
2012 120.632.009.396
2013 164.288.779.106 26.57%
2014 203.848.208.946 19.41%
2015 253.714.672.409 19.65%
2016 295.764.599.133 14.22%
2017 356.639.285.207 17.07%
2018 425.052.697.967 16.1%
2019 212.481.487.771 -100.04%
2020 232.039.084.983 8.43%
2021 542.565.867.329 57.23%
2022 476.930.489.453 -13.76%
2023 593.601.884.412 19.65%
2023 434.042.625.083 -36.76%
2024 400.149.086.220 -8.47%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

PT Sarana Meditama Metropolitan Tbk Net Profit
Year Net Profit Growth
2012 23.269.293.422
2013 46.648.538.059 50.12%
2014 58.068.023.448 19.67%
2015 56.605.341.698 -2.58%
2016 14.795.162.646 -282.59%
2017 72.014.785.065 79.46%
2018 58.883.002.032 -22.3%
2019 -114.385.467.060 151.48%
2020 -449.467.205.524 74.55%
2021 144.169.265.518 411.76%
2022 9.582.695.037 -1404.48%
2023 45.852.690.408 79.1%
2023 12.252.193.946 -274.24%
2024 -25.813.398.892 147.46%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

PT Sarana Meditama Metropolitan Tbk Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2012 3
2013 5 60%
2014 6 16.67%
2015 6 0%
2016 2 -500%
2017 8 85.71%
2018 7 -16.67%
2019 -13 150%
2020 -44 72.09%
2021 11 530%
2022 1 0%
2023 3 100%
2023 1 0%
2024 -2 100%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

PT Sarana Meditama Metropolitan Tbk Free Cashflow
Year Free Cashflow Growth
2012 39.726.840.477
2013 -22.715.201.865 274.89%
2014 59.451.482.363 138.21%
2015 -44.111.568.052 234.78%
2016 -172.774.630.533 74.47%
2017 -12.158.852.900 -1320.98%
2018 -458.349.408.784 97.35%
2019 -180.963.430.027 -153.28%
2020 -28.397.343.331 -537.25%
2021 114.699.203.969 124.76%
2022 -231.134.336.772 149.62%
2023 -356.000.840.544 35.07%
2023 -363.970.820.125 2.19%
2024 -36.186.393.524 -905.82%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

PT Sarana Meditama Metropolitan Tbk Operating Cashflow
Year Operating Cashflow Growth
2012 55.044.972.771
2013 74.802.025.128 26.41%
2014 111.117.253.544 32.68%
2015 97.529.578.906 -13.93%
2016 123.850.340.188 21.25%
2017 66.255.296.191 -86.93%
2018 31.312.617.382 -111.59%
2019 188.400.529.811 83.38%
2020 -21.667.285.017 969.52%
2021 253.740.257.574 108.54%
2022 9.582.695.037 -2547.9%
2023 0 0%
2023 151.547.833.019 100%
2024 26.838.550.138 -464.66%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

PT Sarana Meditama Metropolitan Tbk Capital Expenditure
Year Capital Expenditure Growth
2012 15.318.132.294
2013 97.517.226.993 84.29%
2014 51.665.771.181 -88.75%
2015 141.641.146.958 63.52%
2016 296.624.970.721 52.25%
2017 78.414.149.091 -278.28%
2018 489.662.026.166 83.99%
2019 369.363.959.838 -32.57%
2020 6.730.058.314 -5388.27%
2021 139.041.053.605 95.16%
2022 240.717.031.809 42.24%
2023 356.000.840.544 32.38%
2023 515.518.653.144 30.94%
2024 63.024.943.662 -717.96%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

PT Sarana Meditama Metropolitan Tbk Equity
Year Equity Growth
2012 19.223.383.337
2013 133.010.676.097 85.55%
2014 191.078.923.719 30.39%
2015 741.179.986.378 74.22%
2016 850.972.728.147 12.9%
2017 1.042.283.959.668 18.36%
2018 1.326.090.642.486 21.4%
2019 977.502.945.835 -35.66%
2020 545.823.513.083 -79.09%
2021 4.431.595.838.967 87.68%
2022 3.983.017.980.488 -11.26%
2023 3.983.618.518.352 0.02%
2023 3.981.112.716.442 -0.06%
2024 3.984.923.503.737 0.1%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

PT Sarana Meditama Metropolitan Tbk Assets
Year Assets Growth
2012 290.779.044.158
2013 377.654.879.974 23%
2014 466.660.463.300 19.07%
2015 1.203.219.993.917 61.22%
2016 1.451.906.798.116 17.13%
2017 1.714.734.766.230 15.33%
2018 2.529.031.900.083 32.2%
2019 2.232.894.461.723 -13.26%
2020 1.889.591.124.356 -18.17%
2021 4.948.651.095.330 61.82%
2022 5.140.003.882.433 3.72%
2023 5.364.778.080.980 4.19%
2023 5.321.317.092.655 -0.82%
2024 5.393.204.929.357 1.33%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

PT Sarana Meditama Metropolitan Tbk Liabilities
Year Liabilities Growth
2012 271.555.660.821
2013 244.644.203.877 -11%
2014 275.581.539.581 11.23%
2015 462.040.007.539 40.36%
2016 600.934.069.969 23.11%
2017 672.450.806.562 10.64%
2018 1.202.941.257.597 44.1%
2019 1.255.391.515.888 4.18%
2020 1.343.767.611.273 6.58%
2021 517.055.256.363 -159.89%
2022 1.156.985.901.945 55.31%
2023 1.381.159.562.628 16.23%
2023 1.340.204.376.213 -3.06%
2024 1.408.281.425.620 4.83%

PT Sarana Meditama Metropolitan Tbk Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
96.84
Net Income per Share
0.51
Price to Earning Ratio
602.13x
Price To Sales Ratio
3.16x
POCF Ratio
18.56
PFCF Ratio
-19.15
Price to Book Ratio
1.44
EV to Sales
3.67
EV Over EBITDA
23.55
EV to Operating CashFlow
21.58
EV to FreeCashFlow
-22.26
Earnings Yield
0
FreeCashFlow Yield
-0.05
Market Cap
5.247 Bil.
Enterprise Value
6.098 Bil.
Graham Number
49.23
Graham NetNet
-59.71

Income Statement Metrics

Net Income per Share
0.51
Income Quality
32.43
ROE
0
Return On Assets
0
Return On Capital Employed
0.01
Net Income per EBT
0.48
EBT Per Ebit
0.28
Ebit per Revenue
0.04
Effective Tax Rate
0.08

Margins

Sales, General, & Administrative to Revenue
0.06
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.3
Operating Profit Margin
0.04
Pretax Profit Margin
0.01
Net Profit Margin
0.01

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
16.48
Free CashFlow per Share
-15.98
Capex to Operating CashFlow
1.97
Capex to Revenue
0.34
Capex to Depreciation
2.29
Return on Invested Capital
0.01
Return on Tangible Assets
0
Days Sales Outstanding
59.92
Days Payables Outstanding
56.29
Days of Inventory on Hand
15.47
Receivables Turnover
6.09
Payables Turnover
6.48
Inventory Turnover
23.6
Capex per Share
32.46

Balance Sheet

Cash per Share
9,06
Book Value per Share
232,40
Tangible Book Value per Share
199.69
Shareholders Equity per Share
211.93
Interest Debt per Share
61.13
Debt to Equity
0.27
Debt to Assets
0.18
Net Debt to EBITDA
3.29
Current Ratio
0.86
Tangible Asset Value
3.424 Bil.
Net Current Asset Value
-907 Bil.
Invested Capital
4312616109093
Working Capital
-81 Bil.
Intangibles to Total Assets
0.1
Average Receivables
268 Bil.
Average Payables
187 Bil.
Average Inventory
53816364820
Debt to Market Cap
0.19

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

PT Sarana Meditama Metropolitan Tbk Dividends
Year Dividends Growth
2015 5
2016 5 0%
2017 2 -300%
2018 1 0%

PT Sarana Meditama Metropolitan Tbk Profile

About PT Sarana Meditama Metropolitan Tbk

PT Sarana Meditama Metropolitan Tbk engages in the hospital management of EMC Hospital Pulomas in Pulomas, East Jakarta. The company was founded in 1984 and is based in Jakarta, Indonesia. PT Sarana Meditama Metropolitan Tbk is a subsidiary of PT Elang Mahkota Teknologi Tbk.

CEO
Mr. Jusup Halimi
Employee
2.740
Address
Jalan Pulomas Barat VI No. 20
Jakarta, 13210

PT Sarana Meditama Metropolitan Tbk Executives & BODs

PT Sarana Meditama Metropolitan Tbk Executives & BODs
# Name Age
1 Mr. Armen Antonius Djan
Finance Director, Chief Financial Officer & Director
70
2 Dr. Meta Dewi Thedja M.D., Ph.D.
Medical Director & Director
70
3 Mr. Jusup Halimi
President Director & Chief Executive Officer
70
4 Emiliana Maria Tunardy
Head of Corporate Procurement and Project & Asset Management Director
70
5 Ms. Rahmiyati Yahya
Corporate Secretary
70
6 Dr. G.A. Kusmiati
Special Project Director & Director
70
7 Christian Augusta
Head of Business Performance Analysis & Development
70
8 Ms. - Nailufar
Head of Sales & Marketing and Director
70
9 Ms. Agnes Pricilia Suryanto
Head of Internal Audit Unit
70
10 Bambang Syumanjaya
HR Director
70

PT Sarana Meditama Metropolitan Tbk Competitors